Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

The Department of War, through the Defense Health Agency, is soliciting quotes under solicitation HT9402-26-Q-9301 to establish Uniform Formulary Blanket Purchase Agreements and Uniform Formulary Additional Discount Program Agreements for pharmaceutical agents within two specific drug classes: ADHD Stimulants and BRAF-MEK Inhibitors. The procurement is mandated by 10 U.S.C. §1074g and implemented under 32 CFR §199.21, requiring the Pharmacy and Therapeutics Committee to evaluate both clinical effectiveness and cost effectiveness before recommending drugs for inclusion in the Uniform Formulary and determining their tiered classification as generic, formulary, Basic Core Formulary, Extended Core Formulary, or non-formulary. The submission deadline is June 29, 2026, with a pre-quotation teleconference scheduled for May 13, 2026, and responses must be submitted electronically to the designated point of contact. Offerors must be registered in the System for Award Management with a valid Unique Entity ID, and all pricing must be submitted in NDC-11 format aligned with the contractor’s Federal Supply Schedule contract, including the Industrial Funding Fee. Evaluation is based on a trade-off between cost, including Non-Federal Average Manufacturing Price, Federal Ceiling Price compliance, and Additional Discount Program refund offers, and clinical factors such as formulary tier placement, step therapy designation, and therapeutic equivalence as defined by the FDA's Orange Book. The resulting agreements will govern the supply of pharmaceuticals to Military Treatment Facilities, TRICARE Mail Order Pharmacy, and the TRICARE retail network, with performance centered at the Defense Health Agency's office in San Antonio, Texas. Acceptance of prices and award of the agreements are contingent upon final approval by the Director of the Defense Health Agency following the P&T Committee’s recommendation. Contractors must adhere to strict compliance requirements including automatic termination if the underlying FSS contract is terminated, notification of asset transfers within one business day, mandatory generic substitution for FDA-approved “A” rated equivalents, and exclusion of hospital unit dose and injectable NDCs. Invoicing is handled quarterly based on utilization data, with payment terms of 70 days after reconciliation, and refunds are processed according to TRICARE Retail Refund Program guidelines. Packaging, marking, and delivery terms are not explicitly defined beyond the requirement to comply with formulary and NDC specifications, and no formal contract clauses, inspection details beyond regulatory compliance, or